RO7790121 for Eczema
Recruiting at 5 trial locations
RS
Overseen ByReference Study ID Number: CS45570 https://forpatients.roche.com/
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Recruiting
Sponsor: Hoffmann-La Roche
Prior Safety Data
Trial Summary
What is the purpose of this trial?
The purpose of this study is to assess the efficacy and safety of RO7790121 in participants with moderate to severe atopic dermatitis (AD).
Research Team
CT
Clinical Trials
Principal Investigator
Hoffmann-La Roche
Eligibility Criteria
This trial is for people with moderate to severe atopic dermatitis (AD), confirmed by a dermatologist. Participants should have been diagnosed at least one year ago and must use an additive-free emollient daily for a week before starting the study.Inclusion Criteria
Moderate to severe AD
I have used a simple moisturizer every day for at least a week.
AD diagnosis confirmed by a dermatologist according to the Hanifin/Rajka criteria at least 1 year prior to screening
Exclusion Criteria
I have a weakened immune system from birth or due to a condition.
I haven't taken strong steroids by mouth or injection recently.
I haven't needed strong antibiotics for infections or skin conditions in the last month.
See 3 more
Treatment Details
Interventions
- RO7790121 (Monoclonal Antibodies)
Trial OverviewThe trial is testing RO7790121, which is being compared to a placebo to see if it's effective and safe in treating AD. Participants will be randomly assigned to receive either the actual medication or a placebo.
Participant Groups
4Treatment groups
Experimental Treatment
Placebo Group
Group I: RO7790121 Group IIIExperimental Treatment1 Intervention
Participants will receive RO7790121 via SC injection.
Group II: RO7790121 Group IIExperimental Treatment1 Intervention
Participants will receive RO7790121 via SC injection.
Group III: RO7790121 Group IExperimental Treatment1 Intervention
Participants will receive RO7790121 via subcutaneous (SC) injection.
Group IV: PlaceboPlacebo Group1 Intervention
Participants will receive placebo via SC injection.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Hoffmann-La Roche
Lead Sponsor
Trials
2,482
Recruited
1,107,000+
Headquarters
Basel, Switzerland
Known For
Precision medicine
Top Products
Avastin, Herceptin, Rituxan, Accu-Chek
Dr. Levi Garraway
Hoffmann-La Roche
Chief Medical Officer since 2019
MD from the University of Basel
Dr. Thomas Schinecker
Hoffmann-La Roche
Chief Executive Officer since 2023
PhD in Molecular Biology from New York University